Elite in Turcot Syndrome

Thierry Andre

Paris, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Turcot Syndrome
Paris, FR 
OverviewLocationsClinical Research

Overview

Thierry Andre practices in Paris, France. Mr. Andre is rated as an Elite expert by MediFind in the treatment of Turcot Syndrome. His top areas of expertise are Colorectal Cancer, Turcot Syndrome, Lynch Syndrome, Hepato-Pancreato-Biliary Surgery, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 339 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles in the study of Turcot Syndrome.

Gender
Male

Locations

Paris, France
Other Locations
Marseille, France
Villejuif, France
Lyon, France
Grenoble, 38000, France
Mondonville-saint-jean, 31700, France
Creteil, 94010, France
Saint Antoine, France
Blagnac, 31700, France
Clichy-sous-bois, France
Senlis, France
Toulouse, France
Pierre-la-treiche, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: May 01, 2025
Intervention Type: Genetic
Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma: An Open-label GERCOR Phase II Study
Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma: An Open-label GERCOR Phase II Study
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.
Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
Enrollment Status: Completed
Publish Date: January 05, 2024
Intervention Type: Drug
Study Drug: Imatinib Maintenance
Study Phase: Phase 3
Phase Ib/II Trial Evaluating the Safety, Tolerability and Immunological Activity of Durvalumab (MEDI4736) (Anti-PD-L1) Plus Tremelimumab (Anti-CTLA-4) Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Phase Ib/II Trial Evaluating the Safety, Tolerability and Immunological Activity of Durvalumab (MEDI4736) (Anti-PD-L1) Plus Tremelimumab (Anti-CTLA-4) Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: February 10, 2023
Intervention Type: Drug
Study Drugs: Durvalumab, Tremelimumab, FOLFOX
Study Phase: Phase 1/Phase 2
Evaluation of an Immunomodulatory Maintenance Treatment in Patients With Metastatic Colorectal Cancer With Tumor Reduction During Induction Treatment
Evaluation of an Immunomodulatory Maintenance Treatment in Patients With Metastatic Colorectal Cancer With Tumor Reduction During Induction Treatment
Enrollment Status: Unknown
Publish Date: September 10, 2019
Intervention Type: Drug, Other
Study Drug: MGN1703
Study Phase: Phase 3
A Phase Ib Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer - DOUBLIRI
A Phase Ib Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer - DOUBLIRI
Enrollment Status: Completed
Publish Date: January 31, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

339 Total Publications

The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.
The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.
Journal: JAMA oncology
Published: October 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Andre's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 28 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile